Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks
Source: SeekingAlpha
2025-05-12 13:19:58 ET
Summary
- Genfit's Iqirvo, approved for PBC, generated $26M in Q1 2025, but faces competition from Gilead’s Livdelzi, limiting its market potential.
- Genfit's focus is now on developing drugs for ACLF, a high-risk area with no approved treatments, making it a speculative investment.
- Given the high risks and speculative nature of Genfit's ACLF pipeline, I rate GNFT as a Hold, suitable for a barbell portfolio.
Introduction
Read the full article on Seeking Alpha
For further details see:
Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks
Genfit
NASDAQ: GNFTF
GNFTF Trading
-16.98% G/L:
$7.87 Last:
1,000 Volume:
$9.48 Open:
GNFTF Latest News
March 09, 2026 01:00:00 pm
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
February 26, 2026 12:00:00 pm
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
GNFTF Stock Data
$361,801,977
47,868,958
N/A
30
N/A
Biotechnology & Life Sciences
Healthcare
FR
Loos
